EMAS position statement: Testosterone replacement therapy in the aging male


Creative Commons License

Dimopoulou C., Ceausu I., Depypere H., Lambrinoudaki I., Mueck A., Perez-Lopez F. R. , ...More

MATURITAS, vol.84, pp.94-99, 2016 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 84
  • Publication Date: 2016
  • Doi Number: 10.1016/j.maturitas.2015.11.003
  • Title of Journal : MATURITAS
  • Page Numbers: pp.94-99

Abstract

Introduction: Late-onset hypogonadism (LOH) represents a common clinical entity in aging males, characterized by the presence of symptoms (most usually of a sexual nature, such as decreased libido, decreased spontaneous erections and erectile dysfunction) and signs, in combination with low serum testosterone concentrations. Whether testosterone replacement therapy (TRT) should be offered to those individuals is still under extensive debate.